Apogee Therapeutics Inc. (NASDAQ: APGE) is one of the best up and coming stocks with huge upside potential. On August 28, ...

Amlitelimab use in patients with moderate to severe AD was associated with significant improvements in COAs for up to 52 weeks.

Panelists discuss how biologic therapy selection depends on disease burden rather than just body surface area (BSA), with ...

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab ...

L iving with atopic dermatitis can be challenging for anyone, but if someone you love has eczema, it can be particularly tough. About 13 percent of children in the United States have atopic dermatitis ...

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is currently conducting a Phase 3 clinical study ...

Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

Pamela Fantus, a patient with atopic dermatitis, shares her experience with this condition and reflects on the impact it has on her day-to-day life. Pamela Fantus, a patient with atopic dermatitis, ...

Topline results were announced from a phase 3 trial evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

There’s no single test that can diagnose atopic dermatitis (the most common type of eczema). Rather, diagnosing this skin condition requires a careful, multifaceted investigation of signs and symptoms ...